<DOC>
	<DOCNO>NCT01770106</DOCNO>
	<brief_summary>The aim study compare effect denosumab current standard treatment cortical trabecular microarchitecture radius second metacarpal rheumatoid arthritis ( RA ) patient low bone mineral density use high resolution peripheral quantitative compute tomography ( HR-pQCT ) 6-month open-label randomize control study . Forty ambulatory Chinese female , consent receive alendronate standard treatment subjective randomization , enrol study . Subjects randomize 2 arm receiving : 1 ) subcutaneous injection denosumab 60mg ( Prolia® ) every 6 month ( n=20 ) , 2 ) oral alendronate weekly ( Fosamax® weekly 70 mg , n=20 ) . In addition , patient give daily calcium supplement ( 1500mg caltrate /day ) 1 multivitamin tablet per day . Efficacy safety assessment perform baseline , month 3 month 6. aBMD lumbar spine , total hip non-dominant distal radius measure use dual-energy X-ray absorptiometry ( DXA ) microarchitecture bone measure non-dominant distal radius second metacarpal bone non-dominant hand use HR-pQCT .</brief_summary>
	<brief_title>RA Denosumab Bone Microstructure Study</brief_title>
	<detailed_description>Rheumatoid arthritis ( RA ) chronic , systemic inflammatory disease typical woman . Generalized osteoporosis common RA , axial appendicular skeleton female male . Denosumab fully humanize IgG monoclonal antibody target receptor activator nuclear factor κB ligand ( RANKL ) . Denosumab prevent bind activation RANK receptor osteoclasts hence inhibits osteoclasts formation , activation , function survival . Denosumab result rapid great reduction bone remodel correspondingly great increase areal bone mineral density ( aBMD ) skeletal site . Denosumab approve FDA June 2010 treatment postmenopausal woman osteoporosis high risk fracture . Denosumab ( Prolia® ) also license Hong Kong . A high-resolution peripheral quantitative compute tomography ( HR-pQCT ) capable achieve isotropic voxel size 80μm tolerable radiation dos ( 3μSv ) available assessment trabecular cortical microarchitecture distal radius tibia . This technique bear excellent precision density microstructure measure . Denosumab 's great potency suppress bone remodel great effect areal BMD alendronate , particularly predominantly cortical site distal third radius , may reflect differ mechanism action drug , , turn , influence bone microarchitecture . The aim study compare effect denosumab current standard treatment cortical trabecular microarchitecture radius second metacarpal RA patient low bone mineral density use HR-pQCT 6-month open-label randomize control study . One bisphosphonate , namely alendronate sodium ( alendronate ) chosen generate heterogeneous comparable active control group . This 6-month open-label randomize controlled clinical trial . Forty ambulatory Chinese female , consent receive alendronate standard treatment subjective randomization , enrol rheumatology clinic Prince Wales Hospital study . Subjects randomize 2 group receive : 1 ) subcutaneous injection denosumab 60mg ( Prolia® ) every 6 month ( n=20 ) , 2 ) standard treatment : oral alendronate weekly ( Fosamax® weekly 70 mg , n=20 ) . In addition , patient give daily calcium supplement ( 1500mg caltrate /day ) 1 multivitamin tablet per day . Efficacy safety assessment perform baseline , month 3 month 6. aBMD lumbar spine , total hip non-dominant distal radius measure use dual-energy X-ray absorptiometry ( DXA ) microarchitecture bone measure non-dominant distal radius second metacarpal bone non-dominant hand use HR-pQCT .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>diagnosis RA accord 2010 new 2010 American College Rheumatology/ European League Against Rheumatism classification criterion age 18 year old lumbar spine , total hip distal radius Tscore low 1.5 DXA without severe deformity metacarpophalangeal ( MCP ) joint would influence longitudinal assessment HRpQCT consent receive alendronate randomize standard treatment group . previous use denosumab , teriparatide , alendronate antiresorptive agent ; history recent major gastrointestinal ( GI ) tract disease ( e.g . oesophagitis GI ulceration ) experience previous adverse reaction bisphosphonate therapy ; receive boneactive drug , hormonal replacement therapy , thyroxine , thiazide diuretic ; condition affect bone metabolism ; contraindication alendronate denosumab ( uncorrected hypocalcemia ) ; unexplained hypocalcemia ; severe renal impairment serum creatinine level &gt; 200umol/L ; pregnant breastfeeding ; understand Chinese incompetent give consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Bone density</keyword>
	<keyword>Bone microarchitecture</keyword>
	<keyword>HR-pQCT</keyword>
</DOC>